| Literature DB >> 31490092 |
Claudia Di Lorenzo Oliveira1, Shannon Kelly2, Cesar de Almeida-Neto3, Anna Barbara Carneiro-Proietti4, Fabiana Chagas Camargos Piassi5, Tassila Salomon4, Miriam V Flor-Park6, Claudia Maximo7, Daniela Werneck Rodrigues4, Rosimere Afonso Mota4, Carolina Miranda Teixeira4, Paula Loureiro8, Ester Cerdeira Sabino9, Brian Custer2.
Abstract
Sickle cell disease (SCD) affects more than 13 million people and can have a significant impact on the quality of life (QoL) of those persons. We performed a cross-sectional study to evaluate the QoL in SCD children 8-12 years old enrolled from November 2014 to March 2016 in a large multicenter cohort study in Brazil. The PedsQL™ SCD Module was used to evaluate QoL in 412 children from six Brazilian health centers. The mean age of participants was 10.5 years and 193(46.7%) were women. The mean global score was 60.7, with a Cronbach´s alpha of 0.92. There were significant differences in socioeconomic demographics and treatments among participants at the six centers, but age, income, SCD genotype, and use of hydroxyurea did not significantly affect the QoL scores. After adjustment for all of these variables in a linear regression model, a significant difference was observed by site in global QoL score and the dimensions 'worry II'(β0 = 20.7, p < .00), 'treatment´(β0 = 66.8, p < .00) and communication II'(β0 = 45.8, p < .00). These dimensions are affected by the capacity of health professionals to provide clinical and psychological support to patients. Our results suggest that QoL of this patient population varied according the health center even adjusted by sociodemographics characteristics. Additional training of health professionals in psychological and clinical support could directly reduce patient apprehension about the disease its clinical complications.Entities:
Keywords: Children; PedsQL; quality of life; sickle cell disease
Mesh:
Year: 2019 PMID: 31490092 PMCID: PMC6872937 DOI: 10.1080/08880018.2019.1660743
Source DB: PubMed Journal: Pediatr Hematol Oncol ISSN: 0888-0018 Impact factor: 1.969